Published in final edited form as:

Gene. 2015 December 01; 573(2): 188–197. doi:10.1016/j.gene.2015.09.008.

Cardiac myosin-binding protein C (*MYBPC3*) in cardiac pathophysiology

Lucie Carrier^{1,2,*}, Giulia Mearini^{1,2}, Konstantina Stathopoulou^{1,2}, Friederike Cuello^{1,2}

¹Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

²DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany

Abstract

More than 350 individual *MYBPC3* mutations have been identified in patients with inherited hypertrophic cardiomyopathy (HCM), thus representing 40–50% of all HCM mutations, making it the most frequently mutated gene in HCM. HCM is considered a disease of the sarcomere and is characterized by left ventricular hypertrophy, myocyte disarray and diastolic dysfunction. *MYBPC3* encodes for the thick-filament associated protein cardiac myosin-binding protein C (cMyBP-C), a signaling node in cardiac myocytes that contributes to the maintenance of sarcomeric structure and regulation of contraction and relaxation.

This review aims to provide a succinct overview of how mutations in *MYBPC3* are considered to affect the physiological function of cMyBP-C, thus causing the deleterious consequences observed in HCM patients. Importantly, recent advances to causally treat HCM by repairing *MYBPC3* mutations by gene therapy are discussed here, providing a promising alternative to heart transplantation for patients with a fatal form of neonatal cardiomyopathy due to bi-allelic truncating *MYBPC3* mutations.

Keywords

MYBPC3; cardiac myosin-binding protein C; cardiomyopathies; hypertrophy posttranslational modifications; gene therapy

*Corresponding author at: Department of Experimental Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, Germany; Tel: +49-40-7410-57208; Fax: +49-40-7410-55925. carrier@uke.de (L. Carrier).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest statement

The University Medical Center Hamburg-Eppendorf has filed a patent in the area of *MYBPC3* gene therapy using AAV9 for the treatment of hypertrophic cardiomyopathy. All authors have read the journal's policy on disclosure of potential conflict of interest.

1. Introduction

One of the first major steps in understanding the structure and function of *MYBPC3* (OMIM #600958), encoding cardiac myosin-binding protein C (cMyBP-C) has been the cloning of the human cDNA and localization of the gene on human chromosomal 11p11.2 by the group of Labeit (Gautel et al., 1995) (hg 19/GCRh37 reference chr11:47,353,396–47,374,253, and ENST00000545968, NM_000256.3). *MYBPC3* became therefore the “best” candidate gene for the *CMH4* locus for hypertrophic cardiomyopathy (HCM) that was previously mapped by the group of Schwartz (Carrier et al., 1993). Another major step has been the simultaneous identification of the first two *MYBPC3* mutations segregating in HCM families by the respective groups of Schwartz and Seidman (Bonne et al., 1995; Watkins et al., 1995). *MYBPC3* was thus chronologically the fourth HCM gene, following *MYH7*, encoding β -myosin heavy chain (Geisterfer-Lowrance et al., 1990), *TNNT2* and *TPM1*, encoding cardiac troponin T and α -tropomyosin, respectively (Thierfelder et al., 1994), earmarking HCM as a disease of the sarcomere. The evidence that *MYBPC3* defects result in an inherited cardiomyopathy brought back the interest in understanding the function of cMyBP-C in the cardiac sarcomere.

The structure and sequence of the human *MYBPC3* gene have been determined in 1997 (Carrier et al., 1997). It encompasses more than 21 kbp and is composed of 35 exons, including 34 coding (Figure 1). MyBP-C is a multi-modular structural protein component of the sarcomere. It decorates the C-zone of the A band, forming doublet appearing transverse stripes approximately 43 nm apart of each other in the cross-bridge bearing region (Figure 2) (Luther et al., 2008), reviewed by (Schlossarek et al., 2011). Three highly homologous isoforms of MyBP-C exist in adult human muscle: the slow skeletal (encoded by the *MYBPC1* gene which resides on chromosome 12q23.3), the fast skeletal (encoded by the *MYBPC2* gene which resides on chromosome 19q33.3) and the cardiac isoform (cMyBP-C). The cardiac isoform is specifically expressed in the heart during human and mouse development (Fougerousse et al., 1998). cMyBP-C consists of eight immunoglobulin-like and three fibronectin-like domains (Figure 1). In comparison to the slow and fast skeletal isoforms, cMyBP-C has characteristic structural additions, making it an ideal platform for signalling. These include an additional immunoglobulin-like domain at the N-terminus (C0 domain), multiple phosphorylation sites in the MyBP-C motif (M motif) between the immunoglobulin-like domains C1 and C2 and a 28-amino acid insertion within the C5 domain (for reviews, see (Carrier et al., 1998; Flashman et al., 2004; Barefield and Sadayappan, 2010; Schlossarek et al., 2011; Pfuhl and Gautel, 2012; Sadayappan and de Tombe, 2012)).

2. *MYBPC3* and inherited cardiomyopathies

2.1. *MYBPC3* mutations

2.1.1. *MYBPC3* and hypertrophic cardiomyopathy—More than 350 individual *MYBPC3* mutations have been identified causing HCM and thus representing 40–50% of all HCM mutations, making it the most frequently mutated gene in HCM (for reviews, see (Schlossarek et al., 2011; Behrens-Gawlik et al., 2014)). HCM is a myocardial disease characterized by left ventricular hypertrophy, myocardial disarray and diastolic dysfunction

(for reviews, see (Authors/Task Force et al., 2014; Olivotto et al., 2015)), with an estimated prevalence based on hypertrophy of 1:500 in young adults (Maron et al., 1995). It is mainly transmitted in an autosomal-dominant fashion and associates with more than 1,000 mutations in at least 10 genes, encoding components of the sarcomere (for reviews, see (Ho et al., 2015; Olivotto et al., 2015)). Most of the known *MYBPC3* mutations (>60%) are truncating mutations, including nonsense mutations, insertions or deletions, splicing or branch point mutations, leading to COOH-terminally truncated cMyBP-C, lacking the major myosin- and/or titin-binding sites (for review, see (Behrens-Gawlik et al., 2014)). The majority of *MYBPC3*-associated HCM mutations are heterozygous and patients often have a late disease onset with a benign disease progression.

2.1.2. *MYBPC3* and other cardiomyopathies—Genetic studies have revealed significant overlap between genotypes and phenotypes as *MYBPC3* mutations can lead to various forms of cardiomyopathies, such as dilated cardiomyopathy (DCM) and left ventricular non-compaction (LVNC), the latter being characterized by prominent trabeculation of the left ventricle and deep intertrabecular recesses (Hoedemaekers et al., 2010; Probst et al., 2011). Importantly, in a large European multi-centre, multi-national study enrolling a cohort of 639 patients with sporadic or familial DCM, *MYBPC3* mutations represented the second highest number of previously reported disease-causing mutations (38/294, i.e.13%; (Haas et al., 2014)). Furthermore, a 25-bp deletion in *MYBPC3* intron 32 (original description 25) leading to a frameshift, initially associated with HCM in 2 families (Waldmuller et al., 2003) has been also found in 13.8 % of patients with distinct inherited cardiomyopathies (including HCM, DCM and restrictive cardiomyopathy). This genetic variant is present in 4% of the population in South Asia and is associated with a 6.99-fold higher risk to develop heart failure (Dhandapany et al., 2009). Together, these studies reveal *MYBPC3* as one of the major mutated genes in cardiomyopathies and heart failure. Similar to HCM, both missense and truncating mutations were found in DCM and LVNC (Hoedemaekers et al., 2010; Probst et al., 2011; Haas et al., 2014).

2.1.3. Founder *MYBPC3* mutations in HCM—Founder *MYBPC3* mutations have been identified in some countries and populations, where they represent a large percentage of HCM cases (Table). Interestingly, all of them are truncating mutations, resulting in shorter cMyBP-C, lacking the phosphorylation M motif and/or major binding domains to other sarcomeric proteins (Table; Figure 1). A founder c.927–2A>G transition in intron 11 that arose >550 years ago is the predominant cause (58%) of HCM in Iceland (Adalsteinsdottir et al., 2014). The c.912_913delTT (original description Int12ASA_2G; (Niimura et al., 1998)) mutation in exon 11 has been found in 19.5% of HCM probands in the Veneto region of Italy (Calore et al., 2015). In The Netherlands, 3 different founder *MYBPC3* mutations, c.2373_2374insG (or 2373dupG), c.2864_2865delCT and c.2827C>T were found in 17%, 2.6% and 1.6% of HCM cases, respectively (for review, see (Christiaans et al., 2010)). In Finland, the c.3183C>T transition (or Gln1061X) in exon 29 accounts for 17% of HCM cases (Jaaskelainen et al., 2004). In Japan, the c.1775delT (or Val592fs/8) in exon 18 was identified in 16% of HCM probands (Kubo et al., 2005). In Tuscany, the c.772G>A transition (original description Glu258Lys; (Niimura et al., 1998)) in exon 6 was found in 14% of HCM cases (Girolami et al., 2006). Finally, another report indicates that the c.1898–

2A>G transition (original description IVS20–2; (Bonne et al., 1995)) in intron 20 appeared about 10 centuries ago and accounts for 8.4% HCM patients in Center-East France (Teirlinck et al., 2012). Therefore, the likelihood to get compound heterozygotes or homozygotes with these truncating mutations in these countries is high.

2.1.4. Bi-allelic *MYBPC3* mutations and pediatric cardiomyopathy—A body of evidence indicates that patients with more than 1 mutation often develop a more severe phenotype (Richard et al., 2003; Haas et al., 2014), and a significant fraction of childhood-onset HCM (14%) is caused by compound genetic variants (Morita et al., 2008). This suggests that a gene-dosage effect might be responsible for manifestations at a younger age. A total of 51 cases of homozygotes or compound heterozygotes have been reported, composed of 26 cases with double truncating mutations (Richard et al., 2003; Lekanne Deprez et al., 2006; Xin et al., 2007; Zahka et al., 2008; Ortiz et al., 2009; Tajsharghi et al., 2010; Marziliano et al., 2012; Schaefer et al., 2014; Wessels et al., 2014), 11 cases with a missense plus a truncating mutations (Richard et al., 2003; Ingles et al., 2005; Morita et al., 2008; Dellefave et al., 2009; Saltzman et al., 2010; Otsuka et al., 2012), and 14 with bi-allelic missense mutations (Nanni et al., 2003; Van Driest et al., 2004; Garcia-Castro et al., 2005; Ingles et al., 2005; Morita et al., 2008; Saltzman et al., 2010; Maron et al., 2012). These studies also showed that all patients with bi-allelic truncating *MYBPC3* mutations are associated with neonatal cardiomyopathy and lead to heart failure and death within the first year of life.

2.2. *MYBPC3*-associated pathomechanisms

A great understanding of how *MYBPC3* mutations lead to the development of inherited cardiomyopathy came from the analyses of human myocardial samples, gene transfer in different cell lines, naturally-occurring or transgenic animal models and more recently disease modeling using induced-pluripotent stem cells (iPSC)-derived cardiac myocytes (for recent reviews, see (Duncker et al., 2015; Eschenhagen et al., 2015)). Although access to human myocardial samples is difficult, at least some studies provided evidence that truncated cMyBP-Cs, resulting from truncating *MYBPC3* mutations are not detectable in human patient samples by Western-immunoblot analysis (Rottbauer et al., 1997; Moolman et al., 2000; Marston et al., 2009; van Dijk et al., 2009). This was supported in heterozygous *Mybp3*-targeted knock-in mice (Vignier et al., 2009), carrying the human c.772G>A transition (i.e. founder mutation in Tuscany (Girolami et al., 2006); Table). These data suggest haploinsufficiency as the main disease mechanism for heterozygous truncating mutations (for reviews, see (Marston et al., 2012; van der Velden et al., 2015)). A body of evidence exists that the mechanisms regulating the expression of mutant allele involve the nonsense-mediated mRNA decay, the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway after gene transfer of mutant *MYBPC3* in cardiac myocytes or in mice *in vivo* ((Sarikas et al., 2005; Bahrudin et al., 2008; Vignier et al., 2009), and for reviews (Mearini et al., 2008; Carrier et al., 2010; Schlossarek et al., 2014)). In contrast to truncating mutations, missense mutations lead, in most of the cases (although difficult to specifically detect), to stable mutant cMyBP-Cs that are, at least in part, incorporated into the sarcomere and could act as poison polypeptides on the structure and/or function of the sarcomere. Homozygous or compound heterozygous mutations are therefore likely subject

to differential regulation depending on whether they are double missense, double truncating or mixed missense/truncating mutations. The homozygous *Mybpc3*-targeted knock-in mice, which genetically mimic the situation of severe neonatal cardiomyopathy are born without phenotype and soon after birth develop systolic dysfunction followed by (compensatory) cardiac hypertrophy (Gedicke-Hornung et al., 2013; Mearini et al., 2013). The human c. 772G>A transition results in low levels of three different mutant *Mybpc3* mRNAs and cMyBP-Cs in homozygous mice, suggesting a combination of haploinsufficiency and polypeptide poisoning as disease mechanism in the homozygous state (Vignier et al., 2009). The combination of external stress (such as neurohumoral stress or aging) and *Mybpc3* mutations have been shown to impair the UPS in mice (Schlossarek et al., 2012a; Schlossarek et al., 2012b), and proteasomal activities were also depressed in patients with HCM (Predmore et al., 2010).

Skinned trabeculae or cardiac myocytes obtained from human patients carrying a *MYBPC3* mutation or from heterozygous and homozygous *Mybpc3*-targeted knock-in mice exhibited higher myofilament Ca^{2+} sensitivity than controls (Witt et al., 2001; van Dijk et al., 2009; Fraysse et al., 2012; van Dijk et al., 2012; Sequeira et al., 2013). Disease-modeling by engineered heart tissue (EHT) technology with cardiac cells from heterozygous or homozygous *Mybpc3*-targeted knock-in mice reproduced observations made in human and mouse studies displaying abbreviated contractions, greater sensitivity to external Ca^{2+} and smaller inotropic responses to various drugs (isoprenaline, EMD 57033 and verapamil) compared to wild-type control EHTs (Stohr et al., 2013). Therefore, EHTs are suitable to model the disease phenotype and recapitulate functional alterations found in HCM mice. Another good system for modeling cardiomyopathies in the cell culture dish is the derivation of cardiac myocytes from iPSC (for a recent review, see (Eschenhagen et al., 2015)). Four reports of human iPSC models of sarcomeric cardiomyopathies have been published in the last three years showing cellular hypertrophy in most of the cases (Sun et al., 2012; Lan et al., 2013; Han et al., 2014; Tanaka et al., 2014), including one with the c.2995_3010del *MYBPC3* mutation that exhibited in addition to hypertrophy contractile variability in the presence of endothelin-1 (Tanaka et al., 2014).

The mechanisms by which *MYBPC3* haploinsufficiency leads to increased myofilament Ca^{2+} sensitivity and the occurrence of a disease phenotype are not fully elucidated. It is obvious that all conditions result in a reduced amount or even complete absence of cMyBP-C (patients, knock-in or knock-out mice, and after cMyBP-C extraction) and are associated with increased Ca^{2+} sensitivity of the myofilaments (Hofmann et al., 1991; Witt et al., 2001; Cazorla et al., 2006; van Dijk et al., 2009; Fraysse et al., 2012; van Dijk et al., 2012; Sequeira et al., 2013; Barefield et al., 2015). Since cMyBP-C has been shown to normally prevent residual crossbridge cycling at low cytosolic Ca^{2+} concentrations in diastole and thereby promote diastolic relaxation (Pohlmann et al., 2007), reduced or absent cMyBP-C could therefore help to explain diastolic dysfunction independent of hypertrophy as the early consequence of *MYBPC3* mutation in heterozygous patients and knock-in mice (Ho et al., 2009; Michels et al., 2009; Fraysse et al., 2012).

3. Lessons learnt from *Mybpc3*-targeted knockout (*Mybpc3*^{-/-}) mice

Indispensable information highlighting the importance of intact cMyBP-C for normal cardiac physiology has evolved from numerous studies in transgenic mice, in which the consequences of ablation of the protein (*Mybpc3*-targeted knockout mice; *Mybpc3*^{-/-}) were investigated.

Constitutive *Mybpc3*^{-/-} mice are born in accordance with the Mendelian inheritance ratios, survive into adulthood and are fertile (Harris et al., 2002; Carrier et al., 2004). Three weeks from birth onwards, *Mybpc3*^{-/-} mice develop severe cardiac hypertrophy with increased heart-weight-to-body-weight-ratios, enlargement of ventricles, increased myofilament Ca²⁺ sensitivity and depressed diastolic and systolic function (Harris et al., 2002; Carrier et al., 2004; Cazorla et al., 2006). Histologically, *Mybpc3*^{-/-} hearts display structural rearrangements similar to those observed in explanted hearts from HCM patients with cardiac myocyte disarray and increased interstitial fibrosis, without obvious alterations in shape or size of single cardiac myocytes. Ultrastructural examination revealed a loss of lateral alignment of adjacent myofibrils with their Z-lines misaligned. Interestingly, an increased number of mitochondria of decreased size were noticed in *Mybpc3*^{-/-} cardiac myocytes (Harris et al., 2002; Carrier et al., 2004; Brickson et al., 2007; Luther et al., 2008). The first lesson from this mouse model learnt is that cMyBP-C is not essential for sarcomere formation during embryogenesis, but is crucial for sarcomere organization and maintenance of normal cardiac function.

Studies performed in chemically permeabilized cardiac myocyte preparations from *Mybpc3*^{-/-} mice further enlightened possible underlying molecular causes of the HCM phenotype in patients. Lack of cMyBP-C resulted in acceleration of crossbridge cycling rates as evidenced by increased loaded shortening and power output, as well as faster rates of force redevelopment (k_{tr}) at submaximal Ca²⁺ concentrations (Korte et al., 2003; Stelzer et al., 2006a; Stelzer et al., 2006b; Chen et al., 2010). This suggests that cMyBP-C regulates the positioning of myosin and actin for interaction and more precisely acts as to constrain actin-myosin interaction, which limits loaded shortening velocity and ultimately power output. This observation can be partially attributed to its N-terminal C1-M-C2 region interacting with the myosin-S2 domain (Gruen and Gautel, 1999; Kunst et al., 2000; Harris et al., 2004; Ababou et al., 2007), which results in a decreased number of crossbridges formed, due to cMyBP-C acting as a tether to the myosin S1 heads, limiting their mobility (Weith et al., 2012) and thus leading to the observed functional consequences described above. Other studies with intact or skinned cardiac myocytes and atrial tissue from *Mybpc3*^{-/-} mice have indicated that cMyBP-C contributes to the regulation of cardiac contraction at short sarcomere length and is required for complete relaxation in diastole (Cazorla et al., 2006; Pohlmann et al., 2007).

Several studies have suggested that the interactions of cMyBP-C with its binding partners vary with its phosphorylation status of the M motif, which contains multiple thoroughly characterised phosphorylation sites that are targeted all by cAMP-dependent protein kinase (PKA) and individually by a variety of other protein kinases (Hartzell and Titus, 1982; Hartzell and Glass, 1984; Gautel et al., 1995; Mohamed et al., 1998; McClellan et al., 2001;

Bardswell et al., 2010; Cuello et al., 2011; Sadayappan et al., 2011). In its dephosphorylated state, cMyBP-C binds predominantly to myosin S2 and brakes crossbridge formation, however, when phosphorylated in response to β -adrenergic stimulation through activating PKA, it favours binding to actin, then accelerating crossbridge formation, enhancing force development and promoting relaxation (Moss et al., 2015). Binding of the N-terminal C0-C1 region of cMyBP-C to actin (Kulikovskaya et al., 2003; Razumova et al., 2006; Rybakova et al., 2011; Weith et al., 2012) contributes to the sensitisation of the thin filament to Ca^{2+} , potentially through interaction with and therefore shift of tropomyosin into its high Ca^{2+} position, which exposes the myosin-binding sites on actin (Mun et al., 2014; Witayavanitkul et al., 2014; Previs et al., 2015). Three-dimensional electron-microscopy of intact sarcomeres with addition of cMyBP-C fragments confirmed that cMyBP-C associates indeed with both, the thick and the thin filament (Zoghbi et al., 2008; Luther et al., 2011; Mun et al., 2011). Recently, a novel hypothesis for the physiological role of cMyBP-C in the regulation of cardiac contractility was postulated by Kampourakis and colleagues, who investigated structural changes of the thin and thick filaments after addition of recombinant C1-M-C2 region of cMyBP-C to chemically permeabilized contracting rat trabeculae (Kampourakis et al., 2014). They found that the N-terminus of cMyBP-C stabilized the ON state of the thin filaments and the OFF state of the thick filaments, leading to a model for the control of heart muscle contraction in which both filament systems are coordinated by cMyBP-C.

4. Phosphorylation and other “exotic” posttranslational modifications of cMyBP-C

Additionally to alterations in the protein content of cMyBP-C leading to haploinsufficiency and polypeptide poisoning in HCM, cMyBP-C function is also regulated by an ever-growing spectrum of posttranslational modifications (PTMs) with phosphorylation, acetylation, citrullination, and the oxidative PTMs S-glutathiolation, S-nitrosylation and carbonylation.

A large body of literature exists already on the phosphoregulation of cMyBP-C, which has been reviewed in depth elsewhere (Barefield and Sadayappan, 2010; Bardswell et al., 2012; Gupta and Robbins, 2014). In brief, at least three extensively characterized phosphorylation sites (Ser273, 282 and 302; numbering refers to the mouse sequence, Figure 1) are localized in the M motif of cMyBP-C and are targeted by protein kinases in a hierarchical order of events starting with Ser282 that acts as a switch, rendering Ser273 and Ser302 more accessible for phosphorylation. Protein kinases identified thus far to phosphorylate cMyBP-C in the M motif are PKA (Gautel et al., 1995; Mohamed et al., 1998), Ca^{2+} /calmodulin-dependent kinase II (CaMKII; (Sadayappan et al., 2011), p90 ribosomal S6 kinase (RSK; (Cuello et al., 2011), protein kinase D (PKD; (Bardswell et al., 2010; Dirkx et al., 2012) and protein kinase C (PKC; (Mohamed et al., 1998). Furthermore, GSK3 β was described as another protein kinase to phosphorylate cMyBP-C outside the M-domain in the proline-alanine-rich actin-binding site at Ser133 in human myocardium (mouse Ser131; (Kuster et al., 2013)). As described earlier, phosphorylation is required for normal cardiac function, and overall phosphorylation levels of cMyBP-C are reduced in human and experimental heart failure (El-Armouche et al., 2007; Copeland et al., 2010). Transgenic expression of a

phosphomimetic cMyBP-C mutant protected hearts from ischemia-reperfusion injury (Sadayappan et al., 2005; Sadayappan et al., 2006) and reduced the appearance of a 40-kDa proteolytic calpain-degradation fragment of cMyBP-C (Govindan et al., 2012; Witayavanitkul et al., 2014). Taken together, phosphorylation of cMyBP-C is considered beneficial and preservation of phosphorylation combats disease progression. The question arises whether there are good and bad PTMs.

Acetylation was firstly reported by analyzing recombinant cMyBP-C by top-down high-resolution mass spectrometry (Ge et al., 2009) and was later confirmed *in vivo* in mouse hearts subjected to ischemia-reperfusion injury (Govindan et al., 2012). Eight acetylation sites were identified, five of which localized in the N-terminal C0-C1 region (Figure 1). However, whether acetylation of cMyBP-C increases under disease conditions and whether acetylation is functionally important is not fully understood yet. Interestingly, the 40 kDa proteolytic calpain-degradation fragment (Thr272-Arg280) of cMyBP-C was found to be heavily acetylated (Govindan et al., 2012), suggesting that acetylation could promote proteolysis and decrease stability of cMyBP-C in contrast to phosphorylation.

Citrullination (Fert-Bober and Sokolove, 2014) of cMyBP-C was reported to occur, however it has not been functionally characterized with regards to its influence on cMyBP-C function. There is only limited information showing that cMyBP-C is citrullinated at Arg696 in both control and diseased heart tissue (Fert-Bober and Sokolove, 2014).

More importantly, cMyBP-C is also susceptible to oxidation such as S-glutathiolation, S-nitrosylation and carbonylation. S-glutathiolation, the formation of stable mixed disulfides between the sulfhydryl groups of cysteinyl residues with glutathione (Dalle-Donne et al., 2008), was first reported as a reversible oxidative PTM of cMyBP-C in a screen of S-glutathiolated cardiac proteins using *N,N*-biotinyl glutathione disulfide (Brennan et al., 2006). Enhanced S-glutathiolation of a protein migrating at the same molecular mass as cMyBP-C was subsequently reported in mouse heart samples from the deoxycorticosterone acetate-salt hypertensive mouse model and correlated with diastolic dysfunction developed in these animals (Lovelock et al., 2012; Jeong et al., 2013). Further experiments in *in vitro* S-glutathiolated isolated myofibrils and detergent extracted fiber bundles identified three S-glutathiolation sites in murine cMyBP-C (cysteines 479, 627 and 655; Figure 1) and reported to increase myofilament Ca^{2+} sensitivity (Patel et al., 2013). However, under those experimental conditions it cannot be ascertained that S-glutathiolation of cMyBP-C or another myofilament protein is responsible for the observed effects. Experiments in cardiac myocytes with ablation of either the full-length cMyBP-C or mutation of the identified S-glutathiolation sites will be useful to rule out the contribution of other S-glutathiolated proteins. S-nitrosylation was found as another reversible oxidative modification of cMyBP-C. Mouse hearts were perfused with the S-nitrosylating agent S-nitrosoglutathione and analysed by SNO-resin-assisted capture technology coupled tandem mass spectrometry. This identified Cys1270 in cMyBP-C as the site of modification (Figure 1). However, the functional role of S-nitrosylation at that site and whether this occurs *in vivo* has not been investigated yet (Kohr et al., 2011).

Carbonylation of cMyBP-C as an irreversible oxidative modification occurring during conditions of prolonged oxidative stress, was detected after exposure of spontaneously hypertensive rats manipulated to develop breast cancer to the chemotherapeutic ROS-producing drug doxorubicin (Aryal et al., 2014). Carbonylation of cMyBP-C could be an important contributor to cardiac dysfunction observed during chemotherapy (Aryal et al., 2014).

An important future direction will be to decipher the individual role of these newcoming exotic PTMs of cMyBP-C and to establish their contribution in preventing or promoting the development of cardiovascular disease. In this regard, a systematic study of the PTM fingerprint of cMyBP-C under disease conditions, and in relation to the known disease-causing mutations of the *MYBPC3* gene, could provide valuable information to pave the way for new therapeutic avenues to combat heart disease.

5. *MYBPC3*-targeting therapy for inherited cardiomyopathy

Recombinant adeno-associated viruses (AAV) have gained major interest in the past decade as suitable tools for investigating the functional role of individual genes, but also due to their therapeutic potential *in vivo* with selective tissue-tropism and persistent expression of the transgene in post-mitotic tissues (Zacchigna et al., 2014). In combination with the recent development of strategies targeting the endogenous mutation, mutant pre-mRNA or mutant mRNA, it is now possible to envision prevention or cure of inherited cardiomyopathy resulting from *MYBPC3* mutations, particularly of infants with bi-allelic truncating mutations with generally lethal consequences within the first year of life, without alternative therapeutic treatment options except heart transplantation.

Several targeting approaches have been developed in the past decade (Hammond and Wood, 2011; Doudna and Charpentier, 2014). The most recent is genome editing to correct a mutation by CRISPR/Cas9 technology (for review see (Hsu et al., 2014)). Naturally existing as part of the prokaryotic immune system, the CRISPR/Cas9 system has been used for correction of mutations in the mammalian genome (Ran et al., 2013). By inducing nicks in the double-stranded DNA and providing a template DNA sequence, it is possible to repair mutations by homologous recombination. CRISPR/Cas9 genome editing strategy corrected the *Dmd* gene in germline and prevented muscular dystrophy in mice (Long et al., 2014). Furthermore, it modified the *Psk9* gene in mouse liver after adenovirus gene transfer *in vivo* (Ding et al., 2014). This approach has not yet been evaluated for *MYBPC3* mutations, but it could be used for each single or clustered mutation, and therefore applied preferentially for frequent founder *MYBPC3* mutations (Figure 3, Table). The potential of this strategy is currently under investigation in human iPSC lines. However, before translation to a clinical setting, initial teething problems need to be resolved (efficiency, off-target, long-term implications...).

Other strategies targeting the mutant pre-mRNA by exon skipping and/or *trans*-splicing have been evaluated for *MYBPC3*. Exon skipping can be achieved using antisense oligonucleotide (AONs) masking exonic splicing enhancer sequences, which prevent binding of the splicing machinery and therefore result in exclusion of the exon from the

mRNA (Woodley and Valcarcel, 2002; Goyenvalle et al., 2004). This approach can be applied when the resulting shorter, but in-frame translated protein maintains its function. Proof-of-concept of exon skipping was recently shown in *Mybpc3*-targeted knock-in mice (Gedicke-Hornung et al., 2013). AONs directed against exons 5 and 6 were inserted in small nuclear RNA under the control of the U7 promoter and were packaged in tandem in AAV serotype 9, which has a predominant cardiotropism in mice. They induced the removal (i.e. skipping) of exons 5 and 6 and therefore an in-frame deletion, allowing the expression of an alternatively spliced *Mybpc3* mRNA variant, already present at low level in wild-type mice. Systemic administration of AAV-based AONs to *Mybpc3*-targeted knock-in newborn mice prevented both systolic dysfunction and left ventricular hypertrophy, at least for the duration of the investigated period (Gedicke-Hornung et al., 2013). For the human *MYBPC3* gene, skipping of 6 single exons or 5 double exons with specific AONs would result in shortened in-frame cMyBP-Cs, allowing the preservation of the functionally important phosphorylation and protein interaction sites (Figure 3). With this approach, about half of missense or exonic/intronic truncating mutations could be removed, including 35 mutations in exon 25.

Another strategy is the spliceosome-mediated RNA *trans*-splicing. Hereby, two independently transcribed molecules, the mutant pre-mRNA and the therapeutic pre-*trans*-splicing molecule carrying the wild-type sequence are spliced together to give rise to a repaired full-length mRNA (for review see (Wally et al., 2012)). Recently, the feasibility of this method was shown both in isolated cardiac myocytes and *in vivo* in the heart of homozygous *Mybpc3*-targeted knock-in mice, although the efficiency of the process was low and the amount of repaired protein was not sufficient to prevent the development of the cardiac disease phenotype (Mearini et al., 2013). In principle, however, this strategy is superior to exon skipping or CRISPR/Cas9 genome editing and still attractive, because only two pre-*trans*-splicing molecules, targeting the 5' and the 3' of *MYBPC3* pre-mRNA would be sufficient to bypass all *MYBPC3* mutations associated with cardiomyopathies and therefore repair the mRNA (Figure 3).

Finally, we recently showed that AAV-mediated gene transfer of the full-length *Mybpc3* (defined as “gene replacement”, Figure 3) dose-dependently prevents the development of cardiac hypertrophy and dysfunction over a 34-week period in homozygous *Mybpc3*-targeted knock-in mice (Mearini et al., 2014). Unexpectedly, the dose-dependent expression of exogenous *Mybpc3* was concomitantly associated with the down-regulation of endogenous mutant *Mybpc3*. Although the mechanism is not yet fully understood, and since the sarcomeric structure is tightly regulated, we believe that additional expression of a sarcomeric protein is expected to replace partially or completely the endogenous protein level in the sarcomere, as it has been shown in transgenic mice expressing sarcomeric proteins (for review, see (Duncker et al., 2015)). Therefore, this study paved the way for evaluating *MYBPC3* gene therapy in larger animal models, such as the naturally occurring cat model of HCM due to a *MYBPC3* mutation (Meurs et al., 2005), and to translate it to infants suffering from a fatal form of cardiomyopathy caused by *MYBPC3* bi-allelic mutations.

6. Outlook

MYBPC3 mutations are the most frequent mutations causing HCM and constitute a large part of other inherited cardiomyopathies such as DCM and LVNC. Founder mutations have been identified in several countries and are associated with a higher risk to reveal homozygotes or compound heterozygotes, often associated with fatal forms of pediatric cardiomyopathy. For these forms in particular, there is a need for causal therapies. The recent findings that *Mybp3* gene therapy can restore the level of cMyBP-C thus longterm preventing the disease phenotype in mice opens the way for testing this therapy in larger animal models with the vision to prevent heart failure development and decrease mortality in *MYBPC3*-associated pediatric cardiomyopathies.

Acknowledgments

This review and the corresponding Gene Wiki article are written as part of the Gene Wiki Review series-a series resulting from a collaboration between the journal GENE and the Gene Wiki Initiative. The Gene Wiki Initiative is supported by National Institutes of Health (GM089820). Additional support for Gene Wiki Reviews is provided by Elsevier, the publisher of GENE. This work was supported by the DZHK (German Center for Cardiovascular Research), the German Ministry of Research and Education (BMBF), the Association Institut de Myologie (Paris), a grant awarded to F. Cuello by the Deutsche Forschungsgemeinschaft (CU 53/2-1). The authors apologise that they have not been able to mention every important study in this field due to space constraints.

List of abbreviations

AAV	adeno-associated viruses
AON	antisense oligonucleotide
bp	base pair
Ca²⁺	calcium
CaMKII	Ca ²⁺ /calmodulin-dependent kinase II
Chr	chromosome
CK2	casein kinase 2
CMH4	hypertrophic cardiomyopathy, locus 4
cMyBP-C	cardiac myosin-binding protein C
CRISPR	clustered regularly interspaced short palindromic repeats)
DCM	dilated cardiomyopathy
EHT	engineered heart tissue
GSK3β	glycogen-synthase kinase isoform 3β
HCM	hypertrophic cardiomyopathy
iPSC	induced-pluripotent stem cell

k_{tr}	rate of force redevelopment
LMM	light meromyosin
LVNC	left ventricular non-compaction
M or M motif	myosin-binding protein motif
<i>Mybpc3</i> ^{-/-}	myosin-binding protein C knock-out
MYBPC3	human cardiac myosin-binding protein C gene
<i>Mybpc3</i>	mouse cardiac myosin-binding protein C gene
MYH7	human β -myosin-heavy chain gene
PKA	cAMP-dependent protein kinase
PKC	protein kinase C
PKD	protein kinase D
PTM	posttranslational modification
RNS	reactive nitrogen specie
ROS	reactive oxygen species
TNNT2	human cardiac troponin T gene
TPM1	human α -tropomyosin gene
UPS	ubiquitin-proteasome system

References

- Ababou A, Gautel M and Pfuhl M, 2007 Dissecting the N-terminal myosin binding site of human cardiac myosin-binding protein C. Structure and myosin binding of domain C2. *J Biol Chem* 282, 9204–15. [PubMed: 17192269]
- Adalsteinsdottir B, Teekakirikul P, Maron BJ, Burke MA, Gudbjartsson DF, Holm H, Stefansson K, DePalma SR, Mazaika E, McDonough B, Danielsen R, Seidman JG, Seidman CE and Gunnarsson GT, 2014 Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation. *Circulation* 130, 1158–67. [PubMed: 25078086]
- Aryal B, Jeong J and Rao VA, 2014 Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity. *Proc Natl Acad Sci U S A* 111, 2011–6. [PubMed: 24449919]
- Authors/Task Force, m., Elliott PM, Anastakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C and Watkins H, 2014 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *Eur Heart J* 35, 2733–79. [PubMed: 25173338]
- Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E, Igawa O, Takashima S, Mizuta E, Miake J, Yamamoto Y, Shirayoshi Y, Kitakaze M, Carrier L and Hisatome I, 2008 Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation

- and associated with cardiac dysfunction in hypertrophic cardiomyopathy. *J Mol Biol* 384, 896–907. [PubMed: 18929575]
- Bardswell SC, Cuello F, Kentish JC and Avkiran M, 2012 cMyBP-C as a promiscuous substrate: phosphorylation by non-PKA kinases and its potential significance. *J Muscle Res Cell Motil* 33, 53–60. [PubMed: 22089698]
- Bardswell SC, Cuello F, Rowland AJ, Sadayappan S, Robbins J, Gautel M, Walker JW, Kentish JC and Avkiran M, 2010 Distinct sarcomeric substrates are responsible for protein kinase D-mediated regulation of cardiac myofilament Ca²⁺ sensitivity and cross-bridge cycling. *J Biol Chem* 285, 5674–82. [PubMed: 20018870]
- Barefield D, Kumar M, Gorham J, Seidman JG, Seidman CE, de Tombe PP and Sadayappan S, 2015 Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. *J Mol Cell Cardiol* 79, 234–43. [PubMed: 25463273]
- Barefield D and Sadayappan S, 2010 Phosphorylation and function of cardiac myosin binding protein-C in health and disease. *J Mol Cell Cardiol* 48, 866–75. [PubMed: 19962384]
- Behrens-Gawlik V, Mearini G, Geddicke-Hornung C, Richard P and Carrier L, 2014 MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction. *Pflugers Arch* 466, 215–23. [PubMed: 24337823]
- Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S, James M, Beckmann J, Weissenbach J, Vosberg HP, Fiszman M, Komajda M and Schwartz K, 1995 Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. *Nat Genet* 11, 438–40. [PubMed: 7493026]
- Brennan JP, Bardswell SC, Burgoyne JR, Fuller W, Schroder E, Wait R, Begum S, Kentish JC and Eaton P, 2006 Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. *J Biol Chem* 281, 21827–36. [PubMed: 16754666]
- Brickson S, Fitzsimons DP, Pereira L, Hacker T, Valdivia H and Moss RL, 2007 In vivo left ventricular functional capacity is compromised in cMyBP-C null mice. *Am J Physiol Heart Circ Physiol* 292, H1747–54. [PubMed: 17122190]
- Calore C, De Bortoli M, Romualdi C, Lorenzon A, Angelini A, Basso C, Thiene G, Illiceto S, Rampazzo A and Melacini P, 2015 A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life. *J Med Genet* 52, 338–47. [PubMed: 25740977]
- Carrier L, Bonne G, Bahrend E, Yu B, Richard P, Niel F, Hainque B, Cruaud C, Gary F, Labeit S, Bouhour JB, Dubourg O, Desnos M, Hagege AA, Trent RJ, Komajda M, Fiszman M and Schwartz K, 1997 Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. *Circ Res* 80, 427–34. [PubMed: 9048664]
- Carrier L, Bonne G and Schwartz K, 1998 Cardiac myosin binding protein C and hypertrophic cardiomyopathy. *Trends Cardiovasc. Med* 8, 151–156. [PubMed: 21235926]
- Carrier L, Hengstenberg C, Beckmann JS, Guicheney P, Dufour C, Bercovici J, Dausse E, Berebber-bertrand I, Wisniewsky C, Pulvenis D, Fetler L, Vignal A, Weissenbach J, Hillaire D, Feingold J, Bouhour JB, Hagege A, Desnos M, Isnard R, Dubourg O, Komajda M and Schwartz K, 1993 Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. *Nature Genet* 4, 311–313. [PubMed: 8358441]
- Carrier L, Knoell R, Vignier N, Keller DI, Bausero P, Prudhon B, Isnard R, Ambroisine ML, Fiszman M, Ross J Jr., Schwartz K and Chien KR, 2004 Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. *Cardiovasc Res* 63, 293–304. [PubMed: 15249187]
- Carrier L, Schlossarek S, Willis MS and Eschenhagen T, 2010 The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. *Cardiovascular Research* 85, 330–338. [PubMed: 19617224]
- Cazorla O, Szilagyi S, Vignier N, Salazar G, Kramer E, Vassort G, Carrier L and Lacampagne A, 2006 Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. *Cardiovasc Res* 69, 370–80. [PubMed: 16380103]
- Chen PP, Patel JR, Rybakova IN, Walker JW and Moss RL, 2010 Protein kinase A-induced myofilament desensitization to Ca(2+) as a result of phosphorylation of cardiac myosin-binding protein C. *J Gen Physiol* 136, 615–27. [PubMed: 21115695]

- Christiaans I, Nannenberg EA, Dooijes D, Jongbloed RJ, Michels M, Postema PG, Majoor-Krakauer D, van den Wijngaard A, Mannens MM, van Tintelen JP, van Langen IM and Wilde AA, 2010 Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. *Neth Heart J* 18, 248–54. [PubMed: 20505798]
- Copeland O, Sadayappan S, Messer AE, Steinen GJ, van der Velden J and Marston SB, 2010 Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. *J Mol Cell Cardiol* 49, 1003–11. [PubMed: 20850451]
- Cuello F, Bardswell SC, Haworth RS, Ehler E, Sadayappan S, Kentish JC and Avkiran M, 2011 Novel role for p90 ribosomal S6 kinase in the regulation of cardiac myofilament phosphorylation. *J Biol Chem* 286, 5300–10. [PubMed: 21148481]
- Dalle-Donne I, Milzani A, Gagliano N, Colombo R, Giustarini D and Rossi R, 2008 Molecular mechanisms and potential clinical significance of S-glutathionylation. *Antioxid Redox Signal* 10, 445–73. [PubMed: 18092936]
- Dellefave LM, Pytel P, Mewborn S, Mora B, Guris DL, Fedson S, Waggoner D, Moskowitz I and McNally EM, 2009 Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. *Circ Cardiovasc Genet* 2, 442–9. [PubMed: 20031619]
- Dhandapany PS, Sadayappan S, Xue Y, Powell GT, Rani DS, Nallari P, Rai TS, Khullar M, Soares P, Bahl A, Tharkan JM, Vaideeswar P, Rathinavel A, Narasimhan C, Ayapati DR, Ayub Q, Mehdi SQ, Oppenheimer S, Richards MB, Price AL, Patterson N, Reich D, Singh L, Tyler-Smith C and Thangaraj K, 2009 A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. *Nat Genet* 41, 187–91. [PubMed: 19151713]
- Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, Cowan CA, Rader DJ and Musunuru K, 2014 Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. *Circ Res* 115, 488–92. [PubMed: 24916110]
- Dirkx E, Cazorla O, Schwenk RW, Lorenzen-Schmidt I, Sadayappan S, Van Lint J, Carrier L, van Eys GJ, Glatz JF and Luiken JJ, 2012 Protein kinase D increases maximal Ca²⁺-activated tension of cardiomyocyte contraction by phosphorylation of cMyBP-C-Ser315. *Am J Physiol Heart Circ Physiol* 303, H323–31. [PubMed: 22636676]
- Doudna JA and Charpentier E, 2014 Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science* 346, 1258096. [PubMed: 25430774]
- Duncker DJ, Bakkers J, Brundel BJ, Robbins J, Tardiff JC and Carrier L, 2015 Animal-and In Silico Models for the study of Sarcomeric Cardiomyopathies. *Cardiovasc Res*
- El-Armouche A, Pohlmann L, Schlossarek S, Starbatty J, Yeh YH, Nattel S, Dobrev D, Eschenhagen T and Carrier L, 2007 Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. *J Mol Cell Cardiol* 43, 223–9. [PubMed: 17560599]
- Eschenhagen T, Mummery C and Knollmann BC, 2015 Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes. *Cardiovasc Res* 105, 424–38. [PubMed: 25618410]
- Fert-Bober J and Sokolove J, 2014 Proteomics of citrullination in cardiovascular disease. *Proteomics Clin Appl* 8, 522–33. [PubMed: 24946285]
- Flashman E, Redwood C, Moolman-Smook J and Watkins H, 2004 Cardiac myosin binding protein C: its role in physiology and disease. *Circ Res* 94, 1279–89. [PubMed: 15166115]
- Fougerousse F, Delezoide AL, Fiszman MY, Schwartz K, Beckmann JS and Carrier L, 1998 Cardiac myosin binding protein C gene is specifically expressed in heart during murine and human development. *Circ Res* 82, 130–133. [PubMed: 9440712]
- Frayssé B, Weinberger F, Bardswell SC, Cuello F, Vignier N, Geertz B, Starbatty J, Kramer E, Coirault C, Eschenhagen T, Kentish JC, Avkiran M and Carrier L, 2012 Increased myofilament Ca²⁺ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. *J Mol Cell Cardiol* 52, 1299–307. [PubMed: 22465693]
- Garcia-Castro M, Reguero JR, Alvarez V, Batalla A, Soto MI, Albaladejo V and Coto E, 2005 Hypertrophic cardiomyopathy linked to homozygosity for a new mutation in the myosin-binding protein C gene (A627V) suggests a dosage effect. *Int J Cardiol* 102, 501–7. [PubMed: 16004897]

- Gautel M, Zuffardi O, Freiburg A and Labeit S, 1995 Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? *Embo J* 14, 1952–60. [PubMed: 7744002]
- Ge Y, Rybakova IN, Xu Q and Moss RL, 2009 Top-down high-resolution mass spectrometry of cardiac myosin binding protein C revealed that truncation alters protein phosphorylation state. *Proc Natl Acad Sci U S A* 106, 12658–63. [PubMed: 19541641]
- Gedicke-Hornung C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, Schlossarek S, Precigout G, Braren I, Eschenhagen T, Mearini G, Lorain S, Voit T, Dreyfus PA, Garcia L and Carrier L, 2013 Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. *EMBO Mol Med* 5, 1128–45. [PubMed: 23716398]
- Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE and Seidman JG, 1990 A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. *Cell* 62, 999–1006. [PubMed: 1975517]
- Girolami F, Olivetto I, Passerini I, Zachara E, Nistri S, Re F, Fantini S, Baldini K, Torricelli F and Cecchi F, 2006 A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. *J Cardiovasc Med (Hagerstown)* 7, 601–7. [PubMed: 16858239]
- Govindan S, Sarkey J, Ji X, Sundaresan NR, Gupta MP, de Tombe PP and Sadayappan S, 2012 Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro. *J Muscle Res Cell Motil* 33, 17–30. [PubMed: 22527638]
- Goyenvalle A, Vulin A, Fougereousse F, Leturcq F, Kaplan JC, Garcia L and Danos O, 2004 Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. *Science* 306, 1796–9. [PubMed: 15528407]
- Gruen M and Gautel M, 1999 Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin binding protein-C. *J Mol Biol* 286, 933–949. [PubMed: 10024460]
- Gupta MK and Robbins J, 2014 Post-translational control of cardiac hemodynamics through myosin binding protein C. *Pflugers Arch* 466, 231–6. [PubMed: 24145982]
- Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, Feng Z, Muller S, Kayvanpour E, Vogel B, Sedaghat-Hamedani F, Lim WK, Zhao X, Fradkin D, Kohler D, Fischer S, Franke J, Marquart S, Barb I, Li DT, Amr A, Ehlermann P, Mereles D, Weis T, Hassel S, Kremer A, King V, Wirsz E, Isnard R, Komajda M, Serio A, Grasso M, Syrris P, Wicks E, Plagnol V, Lopes L, Gadgaard T, Eiskjaer H, Jorgensen M, Garcia-Giustiniani D, Ortiz-Genga M, Crespo-Leiro MG, Deprez RH, Christiaans I, van Rijsingen IA, Wilde AA, Waldenstrom A, Bolognesi M, Bellazzi R, Morner S, Bermejo JL, Monserrat L, Villard E, Mogensen J, Pinto YM, Charron P, Elliott P, Arbustini E, Katus HA and Meder B, 2014 Atlas of the clinical genetics of human dilated cardiomyopathy. *Eur Heart J*
- Hammond SM and Wood MJ, 2011 Genetic therapies for RNA mis-splicing diseases. *Trends Genet* 27, 196–205. [PubMed: 21497936]
- Han L, Li Y, Tchao J, Kaplan AD, Lin B, Li Y, Mich-Basso J, Lis A, Hassan N, London B, Bett GC, Tobita K, Rasmusson RL and Yang L, 2014 Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. *Cardiovasc Res* 104, 258–69. [PubMed: 25209314]
- Harris SP, Bartley CR, Hacker TA, McDonald KS, Douglas PS, Greaser ML, Powers PA and Moss RL, 2002 Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. *Circ Res* 90, 594–601. [PubMed: 11909824]
- Harris SP, Rostkova E, Gautel M and Moss RL, 2004 Binding of myosin binding protein-C to myosin subfragment S2 affects contractility independent of a tether mechanism. *Circ Res* 95, 930–6. [PubMed: 15472117]
- Hartzell HC and Glass DB, 1984 Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca²⁺-calmodulin-dependent protein kinases. *J Biol Chem* 259, 15587–96. [PubMed: 6549009]
- Hartzell HC and Titus L, 1982 Effects of cholinergic and adrenergic agonists on phosphorylation of a 165,000-dalton myofibrillar protein in intact cardiac muscle. *J Biol Chem* 257, 2111–20. [PubMed: 6276407]

- Ho CY, Carlsen C, Thune JJ, Havndrup O, Bundgaard H, Farrohi F, Rivero J, Cirino AL, Andersen PS, Christiansen M, Maron BJ, Orav EJ and Kober L, 2009 Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. *Circ Cardiovasc Genet* 2, 314–21. [PubMed: 20031602]
- Ho CY, Charron P, Richard P, Girolami F, Van Spaendonck-Zwarts KY and Pinto Y, 2015 Genetic advances in sarcomeric cardiomyopathies: state of the art. *Cardiovasc Res* 105, 397–408. [PubMed: 25634555]
- Hoedemaekers YM, Caliskan K, Michels M, Frohn-Mulder I, van der Smagt JJ, Pfefferkorn JE, Wessels MW, ten Cate FJ, Sijbrands EJ, Dooijes D and Majoer-Krakauer DF, 2010 The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy. *Circ Cardiovasc Genet* 3, 232–9. [PubMed: 20530761]
- Hofmann PA, Hartzell HC and Moss RL, 1991 Alterations in Ca²⁺ sensitive tension due to partial extraction of C-protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers. *J Gen Physiol* 97, 1141–63. [PubMed: 1678777]
- Hsu PD, Lander ES and Zhang F, 2014 Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 157, 1262–78. [PubMed: 24906146]
- Ingles J, Doolan A, Chiu C, Seidman J, Seidman C and Semsarian C, 2005 Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. *J Med Genet* 42, e59. [PubMed: 16199542]
- Jaaskelainen P, Miettinen R, Karkkainen P, Toivonen L, Laakso M and Kuusisto J, 2004 Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. *Ann Med* 36, 23–32. [PubMed: 15000344]
- Jeong EM, Monasky MM, Gu L, Taglieri DM, Patel BG, Liu H, Wang Q, Greener I, Dudley SC Jr. and Solaro RJ, 2013 Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. *J Mol Cell Cardiol* 56, 44–54. [PubMed: 23247392]
- Kampourakis T, Yan Z, Gautel M, Sun YB and Irving M, 2014 Myosin binding protein-C activates thin filaments and inhibits thick filaments in heart muscle cells. *Proc Natl Acad Sci U S A* 111, 18763–8. [PubMed: 25512492]
- Kohr MJ, Aponte AM, Sun J, Wang G, Murphy E, Gucek M and Steenbergen C, 2011 Characterization of potential S-nitrosylation sites in the myocardium. *Am J Physiol Heart Circ Physiol* 300, H1327–35. [PubMed: 21278135]
- Korte FS, McDonald KS, Harris SP and Moss RL, 2003 Loaded shortening, power output, and rate of force redevelopment are increased with knockout of cardiac myosin binding protein-C. *Circ Res* 93, 752–8. [PubMed: 14500336]
- Kubo T, Kitaoka H, Okawa M, Matsumura Y, Hitomi N, Yamasaki N, Furuno T, Takata J, Nishinaga M, Kimura A and Doi YL, 2005 Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese. *J Am Coll Cardiol* 46, 1737–43. [PubMed: 16256878]
- Kulikovskaya I, McClellan G, Flavigny J, Carrier L and Winegrad S, 2003 Effect of MyBP-C binding to actin on contractility in heart muscle. *J Gen Physiol* 122, 1–15.
- Kunst G, Kress KR, Gruen M, Uttenweiler D, Gautel M and Fink RH, 2000 Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. *Circ Res* 86, 51–8. [PubMed: 10625305]
- Kuster DW, Sequeira V, Najafi A, Boontje NM, Wijnker PJ, Witjas-Paalberends ER, Marston SB, Dos Remedios CG, Carrier L, Demmers JA, Redwood C, Sadayappan S and van der Velden J, 2013 GSK3 β phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: short communication. *Circ Res* 112, 633–9. [PubMed: 23277198]
- Lan F, Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Hu S, Ebert AD, Navarrete EG, Simmons CS, Wheeler M, Pruitt B, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT and Wu JC, 2013 Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. *Cell Stem Cell* 12, 101–13. [PubMed: 23290139]

- Lekanne Deprez RH, Muurling-Vlietman JJ, Hruda J, Baars MJ, Wijnaendts LC, Stolte-Dijkstra I, Alders M and van Hagen JM, 2006 Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene. *J Med Genet* 43, 829–32. [PubMed: 16679492]
- Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R and Olson EN, 2014 Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. *Science* 345, 1184–8. [PubMed: 25123483]
- Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ and Dudley SC Jr., 2012 Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. *Circ Res* 110, 841–50. [PubMed: 22343711]
- Luther PK, Bennett PM, Knupp C, Craig R, Padron R, Harris SP, Patel J and Moss RL, 2008 Understanding the organisation and role of myosin binding protein C in normal striated muscle by comparison with MyBP-C knockout cardiac muscle. *J Mol Biol* 384, 60–72. [PubMed: 18817784]
- Luther PK, Winkler H, Taylor K, Zoghbi ME, Craig R, Padron R, Squire JM and Liu J, 2011 Direct visualization of myosin-binding protein C bridging myosin and actin filaments in intact muscle. *Proc Natl Acad Sci U S A* 108, 11423–8. [PubMed: 21705660]
- Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT and Bild DE, 1995 Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. *Circulation* 92, 785–9. [PubMed: 7641357]
- Maron BJ, Maron MS and Semsarian C, 2012 Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. *Heart Rhythm* 9, 57–63. [PubMed: 21839045]
- Marston S, Copeland O, Gehmlich K, Schlossarek S and Carrier L, 2012 How do MYBPC3 mutations cause hypertrophic cardiomyopathy? *J Muscle Res Cell Motil* 33, 75–80. [PubMed: 22057632]
- Marston S, Copeland ON, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C and Watkins H, 2009 Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency. *Circulation Research* 105, 219–222. [PubMed: 19574547]
- Marziliano N, Merlini PA, Vignati G, Orsini F, Motta V, Bandiera L, Intrieri M and Veronese S, 2012 A case of compound mutations in the MYBPC3 gene associated with biventricular hypertrophy and neonatal death. *Neonatology* 102, 254–8. [PubMed: 22907696]
- McClellan G, Kulikovskaya I and Winegrad S, 2001 Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. *Biophys J* 81, 1083–92. [PubMed: 11463649]
- Mearini G, Schlossarek S, Willis MS and Carrier L, 2008 The ubiquitin-proteasome system in cardiac dysfunction. *Biochim Biophys Acta* 1782, 749–63. [PubMed: 18634872]
- Mearini G, Stimpel D, Geertz B, Weinberger F, Krämer E, Schlossarek S, Mourot-Filiatre J, Stöhr A, Dutshc A, Wijner PJM, Braren I, Katus HA, Müller OJ, Voit T, Eschenhagen T and Carrier L, 2014 *Mybpc3* gene therapy for neonatal cardiomyopathy enables longterm disease prevention in mice. *Nat Commun* 5, 5515. [PubMed: 25463264]
- Mearini G, Stimpel D, Kramer E, Geertz B, Braren I, Gedicke-Hornung C, Precigout G, Muller OJ, Katus HA, Eschenhagen T, Voit T, Garcia L, Lorain S and Carrier L, 2013 Repair of *Mybpc3* mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy. *Mol Ther Nucleic Acids* 2, e102. [PubMed: 23820890]
- Meurs KM, Sanchez X, David RM, Bowles NE, Towbin JA, Reiser PJ, Kittleson JA, Munro MJ, Dryburgh K, Macdonald KA and Kittleson MD, 2005 A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. *Hum Mol Genet* 14, 3587–93. [PubMed: 16236761]
- Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D and ten Cate FJ, 2009 Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. *JACC Cardiovasc Imaging* 2, 58–64. [PubMed: 19356534]

- Mohamed AS, Dignam JD and Schlender KK, 1998 Cardiac myosin-binding protein C (MyBP-C): Identification of protein kinase A and protein kinase C phosphorylation sites. *Arch. Biochem. Biophys* 358, 313–319. [PubMed: 9784245]
- Moolman JA, Reith S, Uhl K, Bailey S, Gautel M, Jeschke B, Fischer C, Ochs J, McKenna WJ, Klues H and Vosberg HP, 2000 A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. *Circulation* 101, 1396–402. [PubMed: 10736283]
- Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R, Towbin JA, Seidman JG and Seidman CE, 2008 Shared genetic causes of cardiac hypertrophy in children and adults. *N Engl J Med* 358, 1899–908. [PubMed: 18403758]
- Moss RL, Fitzsimons DP and Ralphe JC, 2015 Cardiac MyBP-C regulates the rate and force of contraction in mammalian myocardium. *Circ Res* 116, 183–92. [PubMed: 25552695]
- Mun JY, Gulick J, Robbins J, Woodhead J, Lehman W and Craig R, 2011 Electron microscopy and 3D reconstruction of F-actin decorated with cardiac myosin-binding protein C (cMyBP-C). *J Mol Biol* 410, 214–25. [PubMed: 21601575]
- Mun JY, Previs MJ, Yu HY, Gulick J, Tobacman LS, Beck Previs S, Robbins J, Warshaw DM and Craig R, 2014 Myosin-binding protein C displaces tropomyosin to activate cardiac thin filaments and governs their speed by an independent mechanism. *Proc Natl Acad Sci U S A* 111, 2170–5. [PubMed: 24477690]
- Nanni L, Pieroni M, Chimenti C, Simionati B, Zimbello R, Maseri A, Frustaci A and Lanfranchi G, 2003 Hypertrophic cardiomyopathy: two homozygous cases with “typical” hypertrophic cardiomyopathy and three new mutations in cases with progression to dilated cardiomyopathy. *Biochem Biophys Res Commun* 309, 391–8. [PubMed: 12951062]
- Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, Roberts R, Sole M, Maron BJ, Seidman JG and Seidman CE, 1998 Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. *N Engl J Med* 338, 1248–57. [PubMed: 9562578]
- Olivotto I, d’Amati G, Basso C, Van Rossum A, Patten M, Emdin M, Pinto Y, Tomberli B, Camici PG and Michels M, 2015 Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. *Cardiovasc Res* 105, 409–23. [PubMed: 25631583]
- Ortiz MF, Rodriguez-Garcia MI, Hermida-Prieto M, Fernandez X, Veira E, Barriales-Villa R, Castro-Beiras A and Monserrat L, 2009 A homozygous MYBPC3 gene mutation associated with a severe phenotype and a high risk of sudden death in a family with hypertrophic cardiomyopathy. *Rev Esp Cardiol* 62, 572–5. [PubMed: 19406073]
- Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, Kitaoka H, Nakamura H, Nakamura K, Okamoto H, Ichida F, Ayusawa M, Nunoda S, Isobe M, Matsuzaki M, Doi YL, Fukuda K, Sasaoka T, Izumi T, Ashizawa N and Kimura A, 2012 Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. *Circ J* 76, 453–61. [PubMed: 22112859]
- Patel BG, Wilder T and Solaro RJ, 2013 Novel control of cardiac myofilament response to calcium by S-glutathionylation at specific sites of myosin binding protein C. *Front Physiol* 4, 336. [PubMed: 24312057]
- Pfuhl M and Gautel M, 2012 Structure, interactions and function of the N-terminus of cardiac myosin binding protein C (MyBP-C): who does what, with what, and to whom? *J Muscle Res Cell Motil* 33, 83–94. [PubMed: 22527637]
- Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Coirault C, Sultan KR, El-Armouche A, Winegrad S, Eschenhagen T and Carrier L, 2007 Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. *Circ Res* 101, 928–38. [PubMed: 17823372]
- Predmore JM, Wang P, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR and Day SM, 2010 Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies. *Circulation* 121, 997–1004. [PubMed: 20159828]
- Previs MJ, Prosser BL, Mun JY, Previs SB, Gulick J, Lee K, Robbins J, Craig R, Lederer WJ and Warshaw DM, 2015 Myosin-binding protein C corrects an intrinsic inhomogeneity in cardiac excitation-contraction coupling. *Sci Adv* 1.

- Probst S, Oechslin E, Schuler P, Greutmann M, Boye P, Knirsch W, Berger F, Thierfelder L, Jenni R and Klaassen S, 2011 Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. *Circ Cardiovasc Genet* 4, 367–74. [PubMed: 21551322]
- Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F, 2013 Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* 8, 2281–308. [PubMed: 24157548]
- Razumova MV, Shaffer JF, Tu AY, Flint GV, Regnier M and Harris SP, 2006 Effects of the N-terminal domains of myosin binding protein-C in an in vitro motility assay: Evidence for long-lived cross-bridges. *J Biol Chem* 281, 35846–54. [PubMed: 17012744]
- Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burbau M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B and Komajda M, 2003 Hypertrophic Cardiomyopathy: Distribution of disease genes, spectrum of mutations and implications for molecular diagnosis strategy. *Circulation* 107, 2227–2232. [PubMed: 12707239]
- Rottbauer W, Gautel M, Zehelein J, Labeit S, Franz WM, Fischer C, Vollrath B, Mall G, Dietz R, Kubler W and Katus HA, 1997 Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. *J Clin Invest* 100, 475–82. [PubMed: 9218526]
- Rybakova IN, Greaser ML and Moss RL, 2011 Myosin binding protein C interaction with actin: characterization and mapping of the binding site. *J Biol Chem* 286, 2008–16. [PubMed: 21071444]
- Sadayappan S and de Tombe PP, 2012 Cardiac myosin binding protein-C: redefining its structure and function. *Biophys Rev* 4, 93–106. [PubMed: 22707987]
- Sadayappan S, Gulick J, Osinska H, Barefield D, Cuello F, Avkiran M, Lasko VM, Lorenz JN, Maillet M, Martin JL, Brown JH, Bers DM, Molkentin JD, James J and Robbins J, 2011 A critical function for ser-282 in cardiac Myosin binding protein-C phosphorylation and cardiac function. *Circ Res* 109, 141–50. [PubMed: 21597010]
- Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn GW 2nd, Klevitsky R, Seidman CE, Seidman JG and Robbins J, 2005 Cardiac myosin-binding protein-C phosphorylation and cardiac function. *Circ Res* 97, 1156–63. [PubMed: 16224063]
- Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG and Robbins J, 2006 Cardiac myosin binding protein c phosphorylation is cardioprotective. *Proc Natl Acad Sci U S A* 103, 16918–23. [PubMed: 17075052]
- Saltzman AJ, Mancini-DiNardo D, Li C, Chung WK, Ho CY, Hurst S, Wynn J, Care M, Hamilton RM, Seidman GW, Gorham J, McDonough B, Sparks E, Seidman JG, Seidman CE and Rehm HL, 2010 Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy. *Circ Res* 106, 1549–52. [PubMed: 20378854]
- Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T and Zolk O, 2005 Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. *Cardiovasc Res* 66, 33–44. [PubMed: 15769446]
- Schaefer E, Helms P, Marcellin L, Desprez P, Billaud P, Chanavat V, Rousson R and Millat G, 2014 Next-generation sequencing (NGS) as a fast molecular diagnosis tool for left ventricular noncompaction in an infant with compound mutations in the MYBPC3 gene. *Eur J Med Genet* 57, 129–32. [PubMed: 24602869]
- Schlossarek S, Englmann DR, Sultan KR, Sauer M, Eschenhagen T and Carrier L, 2012a Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy. *Basic Res Cardiol* 107, 1–13.
- Schlossarek S, Frey N and Carrier L, 2014 Ubiquitin-proteasome system and hereditary cardiomyopathies. *J Mol Cell Cardiol* 71, 25–31. [PubMed: 24380728]
- Schlossarek S, Mearini G and Carrier L, 2011 Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. *J Mol Cell Cardiol* 50, 613–20. [PubMed: 21291890]
- Schlossarek S, Schuermann F, Geertz B, Mearini G, Eschenhagen T and Carrier L, 2012b Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice. *J Muscle Res Cell Motil* 33, 5–15. [PubMed: 22076249]

- Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M and van der Velden J, 2013 Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. *Circ Res* 112, 1491–505. [PubMed: 23508784]
- Stelzer JE, Dunning SB and Moss RL, 2006a Ablation of cardiac myosin-binding protein-C accelerates stretch activation in murine skinned myocardium. *Circ Res* 98, 1212–8. [PubMed: 16574907]
- Stelzer JE, Fitzsimons DP and Moss RL, 2006b Ablation of myosin-binding protein-C accelerates force development in mouse myocardium. *Biophys J* 90, 4119–27. [PubMed: 16513777]
- Stohr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A and Eschenhagen T, 2013 Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. *J Mol Cell Cardiol* 63, 189–98. [PubMed: 23896226]
- Sun N, Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete EG, Hu S, Wang L, Lee A, Pavlovic A, Lin S, Chen R, Hajjar RJ, Snyder MP, Dolmetsch RE, Butte MJ, Ashley EA, Longaker MT, Robbins RC and Wu JC, 2012 Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. *Sci Transl Med* 4, 130ra47.
- Tajsharghi H, Leren TP, Abdul-Hussein S, Tulinius M, Brunvand L, Dahl HM and Oldfors A, 2010 Unexpected myopathy associated with a mutation in MYBPC3 and misplacement of the cardiac myosin binding protein C. *J Med Genet* 47, 575–7. [PubMed: 19858127]
- Tanaka A, Yuasa S, Mearini G, Egashira T, Seki T, Kodaira M, Kusumoto D, Kuroda Y, Okata S, Suzuki T, Inohara T, Arimura T, Makino S, Kimura K, Kimura A, Furukawa T, Carrier L, Node K and Fukuda K, 2014 Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. *J Am Heart Assoc* 3, e001263. [PubMed: 25389285]
- Teirlinck CH, Senni F, Malti RE, Majoor-Krakauer D, Fellmann F, Millat G, Andre-Fouet X, Pernot F, Stumpf M, Boutarin J and Bouvagnet P, 2012 A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death. *BMC Med Genet* 13, 105. [PubMed: 23140321]
- Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, Seidman JG and Seidman CE, 1994 Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. *Cell* 77, 701–12. [PubMed: 8205619]
- van der Velden J, Ho CY, Tardiff JC, Olivetto I, Knollmann BC and Carrier L, 2015 Research priorities in sarcomeric cardiomyopathies. *Cardiovasc Res* 105, 449–56. [PubMed: 25631582]
- van Dijk SJ, Dooijes D, Dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, Ten Cate FJ, Stienen GJ and van der Velden J, 2009 Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy. Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction. *Circulation* 119, 1473–1483. [PubMed: 19273718]
- van Dijk SJ, Paalberends ER, Najafi A, Michels M, Sadayappan S, Carrier L, Boontje NM, Kuster DW, van Slegtenhorst M, Dooijes D, Dos Remedios C, Ten Cate FJ, Stienen GJ and van der Velden J, 2012 Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. *Circ Heart Fail* 5, 36–46. [PubMed: 22178992]
- Van Driest SL, Vasile VC, Ommen SR, Will ML, Tajik AJ, Gersh BJ and Ackerman MJ, 2004 Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 44, 1903–10. [PubMed: 15519027]
- Vignier N, Schlossarek S, Fraysse B, Mearini G, Kramer E, Pointu H, Mougnot N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T and Carrier L, 2009 Nonsense-Mediated mRNA Decay and Ubiquitin-Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathic Mice. *Circ Res* 105, 239–248. [PubMed: 19590044]
- Waldmuller S, Sakthivel S, Saadi AV, Selignow C, Rakesh PG, Golubenko M, Joseph PK, Padmakumar R, Richard P, Schwartz K, Tharakan JM, Rajamanickam C and Vosberg HP, 2003 Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy. *J Mol Cell Cardiol* 35, 623–36. [PubMed: 12788380]

- Wally V, Murauer EM and Bauer JW, 2012 Spliceosome-mediated trans-splicing: the therapeutic cut and paste. *J Invest Dermatol* 132, 1959–66. [PubMed: 22495179]
- Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, Maron BJ, Seidman JG and Seidman CE, 1995 Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. *Nat Genet* 11, 434–7. [PubMed: 7493025]
- Weith A, Sadayappan S, Gulick J, Previs MJ, Vanburen P, Robbins J and Warshaw DM, 2012 Unique single molecule binding of cardiac myosin binding protein-C to actin and phosphorylation-dependent inhibition of actomyosin motility requires 17 amino acids of the motif domain. *J Mol Cell Cardiol* 52, 219–27. [PubMed: 21978630]
- Wessels MW, Herkert JC, Frohn-Mulder IM, Dalinghaus M, van den Wijngaard A, de Krijger RR, Michels M, de Coo IF, Hoedemaekers YM and Dooijes D, 2014 Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects. *Eur J Hum Genet*
- Witayavanitkul N, Ait Mou Y, Kuster DW, Khairallah RJ, Sarkey J, Govindan S, Chen X, Ge Y, Rajan S, Wieczorek DF, Irving T, Westfall MV, de Tombe PP and Sadayappan S, 2014 Myocardial Infarction-induced N-terminal Fragment of Cardiac Myosin-binding Protein C (cMyBP-C) Impairs Myofilament Function in Human Myocardium. *J Biol Chem* 289, 8818–27. [PubMed: 24509847]
- Witt CC, Gerull B, Davies MJ, Centner T, Linke WA and Thierfelder L, 2001 Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. *J Biol Chem* 276, 5353–9. [PubMed: 11096095]
- Woodley L and Valcarcel J, 2002 Regulation of alternative pre-mRNA splicing. *Brief Funct Genomic Proteomic* 1, 266–77. [PubMed: 15239893]
- Xin B, Puffenberger E, Tumbush J, Bockoven JR and Wang H, 2007 Homozygosity for a novel splice site mutation in the cardiac myosin-binding protein C gene causes severe neonatal hypertrophic cardiomyopathy. *Am J Med Genet A* 143A, 2662–7. [PubMed: 17937428]
- Zacchigna S, Zentilin L and Giacca M, 2014 Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. *Circ Res* 114, 1827–46. [PubMed: 24855205]
- Zahka K, Kalidas K, Simpson MA, Cross H, Keller BB, Galambos C, Gurtz K, Patton MA and Crosby AH, 2008 Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish. *Heart* 94, 1326–30. [PubMed: 18467358]
- Zoghbi ME, Woodhead JL, Moss RL and Craig R, 2008 Three-dimensional structure of vertebrate cardiac muscle myosin filaments. *Proc Natl Acad Sci U S A* 105, 2386–90. [PubMed: 18252826]

Highlights

- *MYBPC3* is the most prevalent disease gene in hypertrophic cardiomyopathy.
- Current knowledge regarding the pathomechanisms involved is discussed.
- An overview of cMyBP-C posttranslational modifications and their function is given.
- *MYBPC3*-targeting therapeutic strategies are emphasized.

Figure 1. Schematic representation of *MYBPC3* gene, mRNA and protein structure, its interaction partners (interactome) and sites of posttranslational modifications (PTMs).

MYBPC3 encompasses 21 kbp and is composed of 35 exons, which is transcribed into a 3824-bp transcript. cMyBP-C is a multi-modular protein composed of 8 immunoglobulin-like (C0, C1, C2, C3, C4, C5, C8, C10) and 3 fibronectin-type III (C6, C7, C9) domains. The cardiac isoform differs from the slow-skeletal and the fast-skeletal isoforms by cardiac-specific regions (C0, M, 28-amino acid insertion in C5) that are highlighted in yellow. Between C0 and C1 exists a proline-alanine rich domain (Pro-Ala; PA). The linker between C4 and C5 domains is indicated by a black oval. Anchoring of cMyBP-C to the C-zones of sarcomeric A-bands is mediated by domains C6 to C10. The NH₂-terminus of cMyBP-C interacts with F-actin (C0-M) and the myosin-S2 domain (C1-M-C2). The COOH-terminus of cMyBP-C interacts with members of the four-and-a-half-LIM-domain family (C6-C10), titin (C8-C10) and light meromyosin (LMM; C10). cMyBP-C is subject to a variety of PTMs that are depicted with different coloured diamonds for acetylation (purple), phosphorylation (blue), calpain cleavage site (red), S-glutathiolation (yellow), citrullination (orange), and S-nitrosylation (green). Involved protein kinases are shown below the symbols. Abbreviations used: CaMK, Ca²⁺/calmodulin dependent protein kinase; CK2, casein kinase 2; GSK3 β , glycogen-synthase kinase isoform 3 β ; M, MyBP-C motif; PKA, cAMP-dependent protein kinase; M, MyBP-C motif; PKD, protein kinase D; PKC, protein kinase C; RNS, reactive nitrogen species; ROS, reactive oxygen species; RSK, p90 ribosomal S6 kinase. Numbering of amino acids refers to the mouse sequence.

Figure 2. Schematic diagram depicting sarcomeric localization of cMyBP-C. cMyBP-C (dark blue) localization is restricted to the C-zones of sarcomeric A-bands in 7–9 transverse stripes at both sites of the M-line. Thin filament (light blue), thick filament (middle blue), titin (orange).

Figure 3. Schematic representation of *MYBPC3* gene, mutations and options for causal therapy. *MYBPC3* encompasses 21 kbp and is composed of 35 exons. Exonic missense mutations (blue, total 129) and exonic and intronic truncating mutations (red, total 202) are shown on top of each exon. Causal therapies are shown as a reverse pyramid: i) CRISPR/Cas9 targeting single or a few mutations (purple dotted line), ii) exon skipping targeting all mutations present in one or two exons and associated introns (dark grey), iii) *trans*-splicing targeting either all 5' mutations (exons 1 to 21; left yellow box) or 3' mutations (exons 22 to 35; right yellow box), and finally iv) gene replacement targeting all mutations at once by gene transfer of the full-length *MYBPC3* cDNA (green box). Abbreviations used: CRISPR/Cas9, clustered regularly interspaced short palindromic repeat-associated system. Number of mutations are taken from (Behrens-Gawlik et al., 2014).

Table.

Founder β truncating mutations in HCM patients

Reference	F ¹	Country	Mutation ²	Original description	Location	Protein consequence ³
Adalsteinsdottir et al., 2014	58%	Iceland	c.927-2A>G	Int12ASA_2G	Intron 11	p.Pro309fsX26, PTC in exon 13, truncation in C2
Calore et al., 2015	19.5%	Italy, Veneto	c.912-913delTT	delTT, F305fsd	Exon 11	p.Ser304fsX26, PTC in exon 12, truncation in M
Christiaans et al., 2010	17%	The Netherlands	c.2373_2374insG	2373dupG	Exon 24	p.Trp792fsX17, PTC in exon 25, truncation in C6
Jaaskelainen et al., 2004	17%	Finland	c.3183C>T	Gln1061X	Exon 29	p.Gln1061X, PTC in exon 29, truncation in C8
Kubo et al., 2005	16%	Japan	c.1775delT	Val592fs/8	Exon 18	p.Val592fsX8, PTC in exon 19, truncation in C4
Girolami et al., 2006	14%	Italy, Tuscany	c.772G>A	Glu258Lys	Exon 6	p.Glu258fsX41, PTC in exon 9, truncation in M
Teirlinck et al., 2012	8.4%	France	c.1928-2A>G	IVS20-2	Intron 20	p.Gln643fsX2, PTC in exon 22, truncation in C5
Christiaans et al., 2010	2.6%	The Netherlands	c.2827C>T	2827C>T	Exon 27	p.Arg943X, PTC in exon 27, truncation in C7
Christiaans et al., 2010	1.6%	The Netherlands	c.2864_2865delCT	2864_2865delCT	Exon 27	p.Pro955fsX95, PTC in exon 29, truncation in C8

¹Expressed as total number of cases with HCM.

²cDNA nomenclature, considering the A of ATG Met codon as 1.

³Protein nomenclature, considering ATG Met codon as 1.

Abbreviations used: C2-C8, domains of cardiac myosin-binding protein C; E, frequency of the mutation; M, MyBP-C motif; fs, frameshift; HCM, hypertrophic cardiomyopathy; PTC, premature termination codon; Xn, PTC after n amino acids.